

**CRITICAL REVIEW FORM: ECONOMIC ANALYSIS**

**Citation:** Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt GH, Krahn M, Finfer S, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CD, Muscedere J, Jacka MJ, Klinger J, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade J, Cooper DJ, Cook DJ for the E-PROTECT Investigators for the CCCTG and ANZICS-CTG. Cost-effectiveness of dalteparin versus unfractionated heparin for the prevention of venous thromboembolism in critically ill patients: a prospective comparative economic evaluation of the Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT). JAMA 2014;312(20):2135-2145.

<b>Are the results valid?</b>	
<b>Did the recommendations consider all relevant patient groups, management options, and possible outcomes?</b>	
Did the investigators adopt a sufficiently broad viewpoint?	
Are results reported separately for relevant patient subgroups?	
<b>Is there a systematic review and summary of evidence linking options to outcomes for each relevant question?</b>	
Were costs measured accurately?	
Did investigators consider the timing of costs and outcomes?	
<b>What are the results?</b>	
What were the incremental costs and effects of each strategy?	
Do incremental costs and effects differ between subgroups?	

**CRITICAL REVIEW FORM: ECONOMIC ANALYSIS**

How much does allowance for uncertainty change the results?	
<b>How can I apply the results to patient care?</b>	
Are the treatment benefits worth the harms and the costs?	
Can I expect similar costs in my setting?	

*Adapted from Duke and McMaster Evidence-based Practice Workshops and Users' Guide to the Medical Literature 3<sup>rd</sup> Ed.*